Evidence map›Paper›PMID 27484204›Full record

ArticleWorld journal of urology2017

Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation.

Alp Tuna Beksac, Gerant Rivera-Sanfeliz, Catherine A Dufour, Unwanaobong Nseyo, Zachary Hamilton, Sean W Berquist, Abd-elRahman Hassan, Omer A Raheem, Song Wang, Robert W Wake and 2 more

Abstract read

PubMed Publisher

In one paragraph

Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

Impact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter Analysis.Current oncology (Toronto, Ont.) · 2026
Article
Contrast enhancement early after renal malignancy cryoablation: imaging findings associated with benignity.European radiology · 2023
Article
Intraoperative MRI-derived volumetric ablation margins and initial correlation with local outcome after MRI-guided cryoablation of renal tumors.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023
Article
sABLATE: a simplified ABLATE score for prediction of complications and outcome in percutaneous thermal ablation of renal lesions.Medical oncology (Northwood, London, England) · 2021
Observational
Percutaneous CT-Guided Renal Cryoablation: Technical Aspects, Safety, and Long-Term Oncological Outcomes in a Single Center.Medicina (Kaunas, Lithuania) · 2021
Article
Can multiphase CT scan distinguish between papillary renal cell carcinoma type 1 and type 2?Turkish journal of urology · 2018
Article
Preoperative lipiodol marking and its role on survival and complication rates of CT-guided cryoablation for small renal masses.BMC urology · 2017
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alp Tuna BeksacDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA.

Gerant Rivera-SanfelizDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA.

Catherine A DufourDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA.

Unwanaobong NseyoDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA.

Zachary HamiltonDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA.

Sean W BerquistDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA.

Abd-elRahman HassanDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA.

Omer A RaheemDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA.

Song WangDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA.

Robert W WakeDepartment of Urology, University of Tennessee Health Science Center, Memphis, TN, USA.

Robert E GoldDepartment of Radiology, University of Tennessee Health Science Center, Memphis, TN, USA.

Ithaar H DerweeshDepartment of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Mail Code: 0987, La Jolla, CA, 92093-0987, USA. iderweesh@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe analyzed oncological outcomes in patients who underwent percutaneous renal cryoablation (PRC) with documented renal cell carcinoma (RCC) by perioperative biopsy.

methodsMulticenter retrospective analysis of 153 patients [median follow-up 48 months] who underwent PRC from 09/2005 to 08/2014 was performed. We divided the cohort into patients who developed recurrence versus no recurrence. Kaplan-Meier analyses examined recurrence-free survival (RFS) according to grade and histology. Multivariable analysis (MVA) was performed to identify factors associated with tumor recurrence.

resultsOne hundred and fifty-three patients were analyzed [18 patients (11.8 %) with recurrence and 135 (88.2 %) patients without recurrence]. There were no differences between the groups with respect to demographics, RENAL score, and number of probes utilized. Recurrence group had larger tumor size (3.1 vs. 2.4 cm; p = 0.011), upper pole tumor location (p = 0.016), and greater proportions of high-grade tumor (33 vs. 0.7 %; p < 0.001) and clear cell histology (77.8 vs. 45.9 %; p = 0.011). Four-year RFS was 100 versus 80 % for grade 1 versus grade 2/3 tumors (p = 0.0002), and 97 versus 88 % for other RCC versus clear cell RCC (p = 0.07). MVA demonstrated tumor size >3 cm (OR 2.46; p = 0.019), clear cell histology (OR 2.12; p = 0.027), and high tumor grade (OR 2.33, p < 0.001) as independent risk factors associated with tumor recurrence.

conclusionsAssociation of higher grade and clear cell histology with recurrence and progression suggests need for increased emphasis on preoperative risk stratification by biopsy, with grade 1 and non-clear cell RCC being associated with improved treatment success than higher grade and clear cell RCC.

Indexed as

AgedBiopsyCarcinoma, Renal CellCryosurgeryDisease-Free SurvivalDisease ProgressionFemaleFollow-Up StudiesHumansKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalPrognosisCarcinoma, renal cellPercutaneous renal biopsyPercutaneous renal cryoablationRecurrenceTumor gradeTumor histology

Identifiers

PMID27484204

DOI10.1007/s00345-016-1911-6

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.